Impact of genetic testing on risk-reducing behavior in women at risk for hereditary gynecologic cancer syndromes by Yurgelun, Matthew B et al.
POSTER PRESENTATION Open Access
Impact of genetic testing on risk-reducing
behavior in women at risk for hereditary
gynecologic cancer syndromes
Matthew B Yurgelun
1, Rowena Mercado
2, Margery Rosenblatt
2, Judy E Garber
2, Sapna Syngal
2, Elena M Stoffel
2*
From 13th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer
Honolulu, Hawaii, USA. 16-17 October 2009
Background
Women with hereditary breast and ovarian cancer
(HBOC) have an estimated 15-65% lifetime risk of ovar-
ian cancer; similarly, women with Lynch syndrome have
a 40-60% lifetime risk of endometrial cancer and a
10-12% lifetime risk of ovarian cancer. The aim of this
study was to investigate the impact of genetic testing on
risk-reducing behavior for gynecologic malignancies in
women being tested for HBOC and Lynch syndrome.
Methods
190 women age ≥30 undergoing genetic testing for
HBOC (N=102) or Lynch syndrome (N=88) completed
questionnaires at baseline, 1 month, 3 months, and one
year after testing. Women evaluated for HBOC were
tested for germline BRCAI or BRCA2 gene mutations;
those evaluated for Lynch syndrome were tested for
germline DNA mismatch repair (MMR) gene mutations.
Subjects were asked about personal cancer history, prior
surgeries, cancer screening practices, and genetic test
results. Gynecologic cancer screening was considered
adequate for the HBOC cohort subjects if they had a
transvaginal ultrasound (TYUS) in the past 12 months.
Adequate screening for Lynch cohort subjects was
defined as having had a TVUS and endometrial biopsy
in the past 12 months.
Results
Of the 190 women age ≥30 undergoing genetic testing,
145 subjects (87 HBOC; 58 Lynch) had no prior history
of gynecologic malignancy, hysterectomy, or salpingo-
oophorectomy (BSO) and were thus at risk for gyneco-
logic cancer. Subjects’ mean age was 45.4 years and 52%
(74/141) reported a personal history of any cancer. At
baseline, 40% (34/84) of subjects being tested for HBOC
and 46% (26/57) of those tested for Lynch syndrome
reported prior gynecologic cancer screening.
One-year follow up questionnaires were available on
74 subjects (48 HBOC; 26 Lynch) none of whom had
been diagnosed with a gynecologic cancer in the year
following testing. 92% (11/12) of BRCA mutation-
positive subjects had undergone either BSO (N=8) or
screening with TVUS (N=3). None of the 6 BRCA
mutation-negative subjects had prophylactic surgery or
gynecologic cancer screening. Of those HBOC subjects
with indeterminate or variant genetic test results, 27%
(8/30) had either a BSO (N=3) or TVUS (N=5). 100%
(5/5) of the MMR mutation-positive had undergone
hysterectomy with BSO (N=2) or screening with TVUS
and endometrial biopsy (N=3). None of the 3 MMR
mutation-negative subjects had prophylactic surgery or
gynecologic cancer screening. Of those subjects with
indeterminate or variant genetic test results, 17% (3/18)
had screening; none had prophylactic surgery.
Conclusions
In the first year after genetic testing, women who tested
positive for HBOC or Lynch syndrome increased uptake
of prophylactic surgery or screening to reduce their risk
of gynecologic cancers. Women with true-negative
results do not pursue these unnecessary interventions,
whereas those with indeterminate or variant test results
do not significantly change their risk-reducing
behaviors.
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